Business Wire

Thunder Bridge Capital Partners IV, Inc. and Coincheck Group N.V. Announce Closing of Business Combination

10.12.2024 23:52:00 CET | Business Wire | Press release

Share

Coincheck Group N.V. ordinary shares and warrants to begin trading on Nasdaq on December 11, 2024 as “CNCK” and “CNCKW,” respectively.

Coincheck Group N.V. (“Coincheck”), a Dutch public limited liability company and a holding company of a cryptocurrency trading service company, and Thunder Bridge Capital Partners IV, Inc. (Nasdaq: THCP, THCPU & THCPW) (“Thunder Bridge IV”), a special purpose acquisition company, announced today the consummation of their previously announced business combination. As a result, the ordinary shares and warrants of Coincheck will commence trading on Nasdaq on December 11, 2024 under the new ticker symbols “CNCK” and “CNCKW,” respectively. The business combination was approved at a special meeting of the shareholders of Thunder Bridge IV on December 5, 2024.

“The completion of our business combination with Thunder Bridge IV marks an extraordinary milestone for Coincheck,” said Oki Matsumoto, Representative Executive Officer and Chairman of Monex Group, Inc., and Executive Chairman of Coincheck. “Coincheck was created through the fusion of a robust business foundation built in Japan, combined with the strengths of the U.S. capital markets through the close collaboration of exceptional business and capital markets talent in both Japan and the U.S. We are incredibly proud and excited to become a Nasdaq listed company and for what the future holds for the Coincheck group companies and our shareholders.”

“We are pleased to announce the closing of our merger with the entire Coincheck team,” said Gary Simanson, President and CEO of Thunder Bridge IV. “As a member of the board of directors and CEO of Coincheck, I look forward to partnering with Oki and his team to build one of the preeminent global crypto and Web3 companies in the world.”

Coincheck Group N.V. (“CNCK” and “CNCKW”), is a global holding company, headquartered in the Netherlands, operating in the crypto asset and Web3 domains, and is the parent company of Coincheck, Inc. (“Coincheck Japan”), which operates the regulated crypto asset trading service “Coincheck” in Japan. Coincheck Japan is the leading crypto asset exchange in Japan and is one of the most established and trusted names in crypto. Coincheck Japan has been recognized as Japan’s No.1* most downloaded trading app for five consecutive years. Coincheck is on a mission to “Make Exchange of New Value Easier” by utilizing crypto assets and blockchain technology.

Coincheck Group N.V. is one of only two publicly listed companies on NASDAQ having a crypto asset exchange as its core business. As a newly listed NASDAQ company, and “Your Trusted Global Partner in the Digital World,” Coincheck is well-positioned to further solidify the group’s dominant position in Japan’s crypto asset trading industry and to establish the group as a global player in the crypto and Web3 industry worldwide.

The business combination resulted in gross proceeds of approximately $31.6 million to the combined company, including funds held in a restricted account pursuant to the terms of the previously announced non-redemption agreement, and net of Thunder Bridge IV shareholder redemptions.

J.P. Morgan Securities LLC served as sole financial advisor to Monex Group, Inc., Coincheck Japan’s former direct parent company and now the parent company of Coincheck, in connection with the business combination. Galaxy Digital Partners LLC served as financial advisor to Thunder Bridge IV and Barclays Capital Inc, BTIG, LLC, Cantor Fitzgerald & Co., Inc, Keefe, Bruyette & Woods, Inc., a Stifel Company, and KeyBanc Capital Markets Inc. served as capital markets advisors to Thunder Bridge IV in connection with the business combination. Nelson Mullins Riley & Scarborough LLP, Mori Hamada & Matsumoto, Littler Mendelson P.C. and Allen & Overy LLP served as legal advisors to Thunder Bridge IV and Simpson Thacher & Bartlett LLP, Anderson Mori & Tomotsune, and De Brauw Blackstone Westbroek N.V. served as legal advisors to Coincheck and Monex Group, Inc.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about trading, future financial and operating results, plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning or the negative thereof. These forward-looking statements include, but are not limited to, statements regarding Coincheck’s trading, industry and market sizes, future opportunities for Coincheck , Coincheck Japan and Thunder Bridge IV, Coincheck’s estimated future results and the business combination between Thunder Bridge IV and Coincheck.. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control, which could cause actual results or events to differ materially from those presently anticipated including (i) a delay or failure to realize the expected benefits from the business combination, (ii) risks related to disruption of management’s time from ongoing business operations due to the business combination, (iii) changes in the cryptocurrency and digital asset markets in which Coincheck competes, including with respect to its competitive landscape, technology evolution or regulatory changes, (iv) changes in domestic and global general economic conditions, (v) risk that Coincheck may not be able to execute its growth strategies, including identifying and executing acquisitions, (vi) risk that Coincheck may not be able to develop and maintain effective internal controls and (vii) and other risks and uncertainties discussed in Coincheck’s filings with the U.S. Securities and Exchange Commission. Coincheck undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law.

About Coincheck Group N.V.

Coincheck Group N.V. is a Dutch public limited liability company and a holding company of Coincheck, Inc., , which operates the “Coincheck” cryptocurrency trading service, and has achieved the highest number of app downloads in Japan for 5 consecutive years*. With the mission of “Making Exchange of New Value Easier,” Coincheck, Inc. aims to create better services that allow people to feel the value of new exchanges created by cryptocurrencies and blockchain technologies, through the latest technology and advanced security.

*Target: Cryptocurrency trading app in Japan, Period: January 2019-December 2023, Data cooperation: App Tweak

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210703460/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye